Clinical uses of 22-oxacalcitriol

Current Vascular Pharmacology

Volumn 12, Issue 2, 2014, Pages 324-328

  Mizobuchi, Masahide ^a   Ogata, Hiroaki ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

22 oxacalcitriol; Maxacalcitriol; Percutaneous VDRA injection therapy; Secondary hyperparathyroidism; Vitamin D analogs; Vitamin D receptor activator

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; GELATINASE A; PARATHYROID HORMONE; PHOSPHORUS; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

ARTICLE; BONE METABOLISM; CALCIFICATION; CARDIOVASCULAR DISEASE; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PARATHYROID GLAND; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HYPERPARATHYROIDISM, SECONDARY; PHYSIOLOGY;

ANIMALS; CALCITRIOL; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERPARATHYROIDISM, SECONDARY; RECEPTORS, CALCITRIOL;

EID: 84924450457     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113119990023     Document Type: Article

References (28)

1. [1] Lawson DE, Fraser DR, Kodicek E, et al. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971; 230: 228-30.
2. [2] Brickman AS, Coburn JW, Norman AW. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med 1972; 287: 891-5.
3. [3] Zerwekh JE, Brumbaugh PF, Haussler DH, et al. 1Alpha hydroxyvitamin D3. An analog of vitamin D which apparently acts by metabolism to 1alpha, 25-dihydroxyvitamin D3. Biochemistry 1974; 13: 4097-102.
4. [4] Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984: 74: 2136-43.
5. [5] Dusso AS, Negrea L, Gunawardhana S, et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991; 128: 1687-92.
6. [6] Okano T, Tsugawa N, Masuda S, et al. Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analog of 1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 1989; 35: 529-33.
7. [7] Brown AJ, Finch J, Grieff M, et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158-64.
8. [8] Kobayashi T, Tsugawa N, Okano T, et al. The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25- dihydroxyvitamin D3, a noncalcemic analog of 1 alpha, 25- dihydroxyvitamin D3, in rats. J Biochem 1994; 115: 373-80.
9. [9] Brown AJ, Finch JL, Lopez-Hilker S, et al. New active analogs of vitamin D with low calcemic activity. Kidney Int Suppl 1990; 29: S22-7.
10. [10] Brown, AJ, Ritter, CR, Finch, JL, et al. The noncalcemic analog of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-32.
11. [11] Dusso AS, Negrea L, Finch J, et al. The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 1992; 130: 3129-34.
12. [12] Grieff M, Dusso A, Mori T, et al. 22-oxacalcitriol suppresses 25-hydroxycholecalciferol-1 alpha-hydroxylase in rat kidney. Biochem Biophys Res Commun 1992; 185: 191-6.
13. [13] Brown AJ, Berkoben M, Ritter C, et al. Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells. Biochem Biophys Res Commun 1992; 189: 759-64.
14. [14] Bikle DD, Abe-Hashimoto J, Su MJ, et al. 22-Oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism. J Invest Dermatol 1995; 105: 693-8.
15. [15] Kamimura S, Gallieni M, Kubodera N, et al. Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes. Endocrinology 1993; 133: 2719-23.
16. [16] Kurokawa K, Akizawa T, Suzuki M, et al. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study. Nephrol Dial Transplant 1996; 11 Suppl 3: 121-4.
17. [17] Akizawa T, Ohashi Y, Akiba T, et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004; 8: 480-91.
18. [18] Ogata H, Koiwa F, Shishido K, et al. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2007; 11: 202-9.
19. [19] Mochizuki T, Naganuma S, Tanaka, Y, et al. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study. Clin Nephrol 2007; 67: 12-9.
20. [20] Hayashi M, Tsuchiya Y, Itaya Y, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 2004; 19: 2067-73.
21. [21] Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 2003; 18: 1770-6.
22. [22] Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-64.
23. [23] Chung AW, Yang HH, Kim JM, et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009; 120: 792-801.
24. [24] Aoshima Y, Mizobuchi M, Ogata H, et al. Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-alpha. Nephrol Dial Transplant 2012; 27: 1800-6.
25. [25] Kitaoka M, Fukagawa M, Ogata E, et al. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: 1110-7.
26. [26] Kitaoka M, Onoda N, Kitamura H, et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 2003; 18 Suppl 3: 11138-41.
27. [27] Shiizaki K, Hatamura I, Negi S, et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003; 64: 992-1003.
28. [28] Shiizaki K, Negi S, Hatamura I, et al. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 2005; 16: 97-108.